Related Experiment Videos
Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.
L Durelli1, B Ferrero, A Oggero
1Clinica Neurologica, Dipartimento di Neuroscienze, Universitá di Torino, Italy. luca.durelli@unito.it
Neurology
|October 24, 2001
Summary
Interferon-beta 1b (IFNB) treatment for multiple sclerosis (MS) may increase liver dysfunction, but thyroid issues and autoimmunity changes appear unrelated to IFNB. Further monitoring is recommended for liver function during treatment.
Area of Science:
- Neurology
- Immunology
- Endocrinology
Background:
- Autoimmune diseases and autoantibodies can occur during type I interferon (IFN) therapy.
- Investigating potential side effects of IFN-beta 1b (IFNB) in multiple sclerosis (MS) patients is crucial.
Purpose of the Study:
- To determine the frequency of thyroid and liver dysfunction during IFNB treatment for MS.
- To assess the occurrence of autoimmunity in MS patients undergoing IFNB therapy.
Main Methods:
- A 1-year prospective follow-up study of 156 MS patients across 18 centers.
- Longitudinal analysis using generalized estimating equations (GEE) to track thyroid function, liver function, and autoantibodies (autoAb).
Main Results:
- Thyroid dysfunction occurred in 8.3% of patients de novo during IFNB treatment, with no significant change from baseline.
- Liver alteration significantly increased de novo during IFNB treatment (37.5%), particularly in the first 6 months (p < 0.0001).
- Autoantibody (autoAb) prevalence showed no significant change during IFNB treatment compared to baseline.
Conclusions:
- Liver function alterations during IFNB treatment suggest a probable causal relationship.
- Thyroid dysfunction and autoimmunity changes during IFNB treatment appear transient and not significantly related to the therapy.
- Monitoring liver function is important during IFNB treatment for MS.